Complications associated with recombinant tissue plasminogen activator therapy for acute Ischaemic stroke

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 2, 2013, Pages 155-169

  Balami, Joyce S ^a   Sutherland, Brad A ^b   Buchan, Alastair M ^b  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Alteplase; Clinical complications; Ischaemic stroke; Management; Preclinical complications; Recombinant tissue plasminogen activator

Indexed keywords

ABCIXIMAB; ALTEPLASE; ANTIHISTAMINIC AGENT; CORTICOSTEROID; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; NEUROSERPIN; PLACEBO; PLASMIN; PLASMINOGEN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ANGIONEUROTIC EDEMA; ARTERY REOCCLUSION; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CRANIOTOMY; CYTOKINE PRODUCTION; DEATH; DECOMPRESSION SURGERY; DISEASE SEVERITY; DRUG MECHANISM; DRUG WITHDRAWAL; EMBOLISM; HUMAN; MECHANICAL THROMBECTOMY; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PERFUSION; PRACTICE GUIDELINE; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; RISK FACTOR; SCORING SYSTEM; SEIZURE; SIDE EFFECT; TRANSCRANIAL DOPPLER;

ANIMALS; HUMANS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84876695675     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273112119990050     Document Type: Article

References (179)

1. Balami, J.; Chen, R.L.; Sutherland, B.A.; Buchan, A.M. Thrombolytic agents for acute ischaemic stroke treatment: the past, present and future. CNS Neurol. Disord. Drug Targets, 2013, 12(2), XXX-XXX.
2. Kleindorfer, D.; Xu, Y.; Moomaw, C.J.; Khatri, P.; Adeoye, O.; Hornung, R. US geographic distribution of rt-PA utilization by hospital for acute ischemic stroke. Stroke, 2009, 40(11), 3580-3584.
3. Leyden, J.M.; Chong, W.K.; Kleinig, T.; Lee, A.; Field, J.B.; Jannes, J. A population-based study of thrombolysis for acute stroke in South Australia. Med. J. Aust., 2011, 194(3), 111-115.
4. RCP Royal College of Physicians of London. National Sentinel Stroke Audit Organisational Audit 2010. Public report for England, Wales and Northern Ireland. http://www.rcplondon.ac.uk/sites/default/files/2010-stroke-public-report.pdf (accessed 30/07/2012).
5. Wang, D.Z.; Rose, J.A.; Honings, D.S.; Garwacki, D.J.; Milbrandt, J.C. Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. Stroke, 2000, 31(1), 77-81.
6. Albers, G.W.; Clark, W.M.; Madden, K.P.; Hamilton, S.A. ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Stroke, 2002, 33(2), 493-495.
7. Clark, W.M.; Wissman, S.; Albers, G.W.; Jhamandas, J.H.; Madden, K.P.; Hamilton, S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA, 1999, 282(21), 2019-2026.
8. Hacke, W.; Kaste, M.; Bluhmki, E.; Brozman, M.; Davalos, A.; Guidetti, D.; Larrue, V.; Lees, K.R.; Medeghri, Z.; Machnig, T.; Schneider, D.; von Kummer, R.; Wahlgren, N.; Toni, D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med., 2008, 359(13), 1317-1329.
9. Hacke, W.; Kaste, M.; Fieschi, C.; Toni, D.; Lesaffre, E.; von Kummer, R.; Boysen, G.; Bluhmki, E.; Hoxter, G.; Mahagne, M.H.; Michael, H. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA, 1995, 274(13), 1017-1025.
10. Hacke, W.; Kaste, M.; Fieschi, C.; von Kummer, R.; Davalos, A.; Meier, D.; Larrue, V.; Bluhmki, E.; Davis, S.; Donnan, G.; Schneider, D.; Diez-Tejedor, E.; Trouillas, P. Randomised doubleblind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet, 1998, 352(9136), 1245-1251.
11. NINDS, Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med., 1995, 333(24), 1581-1587.
12. Sandercock, P.; Wardlaw, J.M.; Lindley, R.I.; Dennis, M.; Cohen, G.; Murray, G.; Innes, K.; Venables, G.; Czlonkowska, A.; Kobayashi, A.; Ricci, S.; Murray, V.; Berge, E.; Slot, K.B.; Hankey, G.J.; Correia, M.; Peeters, A.; Matz, K.; Lyrer, P.; Gubitz, G.; Phillips, S.J.; Arauz, A. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet, 2012, 379(9834), 2352-2363.
13. Albers, G.W.; Bates, V.E.; Clark, W.M.; Bell, R.; Verro, P.; Hamilton, S.A. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA, 2000, 283(9), 1145-1150.
14. Hill, M.D.; Buchan, A.M. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ, 2005, 172(10), 1307-1312.
15. Wahlgren, N.; Ahmed, N.; Davalos, A.; Hacke, W.; Millan, M.; Muir, K.; Roine, R.O.; Toni, D.; Lees, K.R. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet, 2008, 372(9646), 1303-1309.
16. Hacke, W.; Donnan, G.; Fieschi, C.; Kaste, M.; von Kummer, R.; Broderick, J.P.; Brott, T.; Frankel, M.; Grotta, J.C.; Haley, E.C. Jr.; Kwiatkowski, T.; Levine, S.R.; Lewandowski, C.; Lu, M.; Lyden, P.; Marler, J.R.; Patel, S.; Tilley, B.C.; Albers, G.; Bluhmki, E.; Wilhelm, M.; Hamilton, S. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet, 2004, 363(9411), 768-774.
17. Lees, K.R.; Bluhmki, E.; von Kummer, R.; Brott, T.G.; Toni, D.; Grotta, J.C.; Albers, G.W.; Kaste, M.; Marler, J.R.; Hamilton, S.A.; Tilley, B.C.; Davis, S.M.; Donnan, G.A.; Hacke, W.; Allen, K.; Mau, J.; Meier, D.; del Zoppo, G.; De Silva, D.A.; Butcher, K.S.; Parsons, M.W.; Barber, P.A.; Levi, C.; Bladin, C.; Byrnes, G. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, 2010, 375(9727), 1695-1703.
18. Wardlaw, J.M.; Murray, V.; Berge, E.; del Zoppo, G.; Sandercock, P.; Lindley, R.L.; Cohen, G. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet, 2012, 379(9834), 2364-2372.
19. Yepes, M.; Roussel, B.D.; Ali, C.; Vivien, D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci., 2009, 32(1), 48-55.
20. Pennica, D.; Holmes, W.E.; Kohr, W.J.; Harkins, R.N.; Vehar, G.A.; Ward, C.A.; Bennett, W.F.; Yelverton, E.; Seeburg, P.H.; Heyneker, H.L.; Goeddel, D.V.; Collen, D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature, 1983, 301(5897), 214-221.
21. Nguyen, T.H.; Ward, C. Stability characterization and formulation development of alteplase, a recombinant tissue plasminogen activator. In Stability and characterization of protein and peptide drugs: case histories, Wang, Y.J.; Pearlman, R. Eds. Plenum Press: New York, 1993; pp. 91-134.
22. Van de Werf, F.; Bergmann, S.R.; Fox, K.A.; de Geest, H.; Hoyng, C.F.; Sobel, B.E.; Collen, D. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation, 1984, 69(3), 605-610.
23. Gold, H.K.; Fallon, J.T.; Yasuda, T.; Leinbach, R.C.; Khaw, B.A.; Newell, J.B.; Guerrero, J.L.; Vislosky, F.M.; Hoyng, C.F.; Grossbard, E. Coronary thrombolysis with recombinant human tissue-type plasminogen activator. Circulation, 1984, 70(4), 700-707.
24. Robbins, K.C.; Summaria, L.; Hsieh, B.; Shah, R.J. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J. Biol. Chem., 1967, 242(10), 2333-2342.
25. Wiman, B.; Lijnen, H.R.; Collen, D. On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. Biochim. Biophys. Acta, 1979, 579(1), 142-154.
26. Keijer, J.; Linders, M.; van Zonneveld, A.J.; Ehrlich, H.J.; de Boer, J.P.; Pannekoek, H. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinasetype) and fibrin: localization of interaction sites and physiologic relevance. Blood, 1991, 78(2), 401-409.
27. Steiner, J.P.; Migliorini, M.; Strickland, D.K. Characterization of the reaction of plasmin with alpha 2-macroglobulin: effect of antifibrinolytic agents. Biochemistry, 1987, 26(25), 8487-8495.
28. Kruithof, E.K.; Baker, M.S.; Bunn, C.L. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood, 1995, 86(11), 4007-4024.
29. Hastings, G.A.; Coleman, T.A.; Haudenschild, C.C.; Stefansson, S.; Smith, E.P.; Barthlow, R.; Cherry, S.; Sandkvist, M.; Lawrence, D.A. Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J. Biol. Chem., 1997, 272(52), 33062-33067.
30. Korninger, C.; Collen, D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb. Haemost., 1981, 46(2), 561-565.
31. Matsuo, O.; Rijken, D.C.; Collen, D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature, 1981, 291(5816), 590-591.
32. Camiolo, S.M.; Thorsen, S.; Astrup, T. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc. Soc. Exp. Biol. Med., 1971, 138(1), 277-280.
33. Hoylaerts, M.; Rijken, D.C.; Lijnen, H.R.; Collen, D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J. Biol. Chem., 1982, 257(6), 2912-2919.
34. Eisenberg, P.R.; Sherman, L.A.; Tiefenbrunn, A.J.; Ludbrook, P.A.; Sobel, B.E.; Jaffe, A.S. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation. Thromb. Haemost., 1987, 57(1), 35-40.
35. Kano, T.; Katayama, Y.; Tejima, E.; Lo, E.H. Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke. Brain Res., 2000, 854(1-2), 245-248.
36. Zivin, J.A.; Fisher, M.; DeGirolami, U.; Hemenway, C.C.; Stashak, J.A. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science, 1985, 230(4731), 1289-1292.
37. Braeuninger, S.; Kleinschnitz, C. Rodent models of focal cerebral ischemia: procedural pitfalls and translational problems. Exp. Transl. Stroke Med., 2009, 1, 8.
38. Brinker, G.; Pillekamp, F.; Hossmann, K.A. Brain hemorrhages after rt-PA treatment of embolic stroke in spontaneously hypertensive rats. Neuroreport, 1999, 10(9), 1943-1946.
39. Dijkhuizen, R.M.; Asahi, M.; Wu, O.; Rosen, B.R.; Lo, E.H. Delayed rt-PA treatment in a rat embolic stroke model: diagnosis and prognosis of ischemic injury and hemorrhagic transformation with magnetic resonance imaging. J. Cereb. Blood Flow Metab., 2001, 21(8), 964-971.
40. Lyden, P.D.; Madden, K.P.; Clark, W.M.; Sasse, K.C.; Zivin, J.A. Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]. Stroke, 1990, 21(11), 1589-1593.
41. Overgaard, K.; Sereghy, T.; Pedersen, H.; Boysen, G. Effect of delayed thrombolysis with rt-PA in a rat embolic stroke model. J. Cereb. Blood Flow Metab., 1994, 14(3), 472-477.
42. Zhang, R.L.; Chopp, M.; Zhang, Z.G.; Divine, G. Early(1 h) administration of tissue plasminogen activator reduces infarct volume without increasing hemorrhagic transformation after focal cerebral embolization in rats. J. Neurol. Sci., 1998, 160(1), 1-8.
43. Won, S.J.; Tang, X.N.; Suh, S.W.; Yenari, M.A.; Swanson, R.A. Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by Increasing superoxide production. Ann. Neurol., 2011, 70(4), 583-590.
44. Sena, E.S.; Briscoe, C.L.; Howells, D.W.; Donnan, G.A.; Sandercock, P.A.; Macleod, M.R. Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. J. Cereb. Blood Flow Metab., 2010, 30(12), 1905-1913.
45. Berger, C.; Fiorelli, M.; Steiner, T.; Schabitz, W.R.; Bozzao, L.; Bluhmki, E.; Hacke, W.; von Kummer, R. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke, 2001, 32(6), 1330-1335.
46. Larrue, V.; von Kummer, R.; del Zoppo, G.; Bluhmki, E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke, 1997, 28(5), 957-960.
47. NINDS, Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke, 1997, 28(11), 2109-2118.
48. Trouillas, P.; von Kummer, R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke, 2006, 37(2), 556-561.
49. Wahlgren, N.; Ahmed, N.; Davalos, A.; Ford, G.A.; Grond, M.; Hacke, W.; Hennerici, M.G.; Kaste, M.; Kuelkens, S.; Larrue, V.; Lees, K.R.; Roine, R.O.; Soinne, L.; Toni, D.; Vanhooren, G. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study(SITS-MOST): an observational study. Lancet, 2007, 369(9558), 275-282.
50. Graham, G.D. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke, 2003, 34(12), 2847-2850.
51. Libman, R.; Kwiakowski, T.; Lyden, P.; Grotta, J.C.; Tilley, B.C.; Fagen, S.C.; Levine, S.R.; Broderick, J.P.; Lin, Y.; Lewandowski, C.; Frankel, M.R. Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long-term outcome. J. Stroke Cerebrovasc. Dis., 2005, 14(2), 50-54.
52. Sloan, M.A.; Sila, C.A.; Mahaffey, K.W.; Granger, C.B.; Longstreth, W.T. Jr.; Koudstaal, P.; White, H.D.; Gore, J.M.; Simoons, M.L.; Weaver, W.D.; Green, C.L.; Topol, E.J.; Califf, R.M. Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. Circulation, 1998, 98(14), 1376-1382.
53. Strbian, D.; Sairanen, T.; Meretoja, A.; Pitkaniemi, J.; Putaala, J.; Salonen, O.; Silvennoinen, H.; Kaste, M.; Tatlisumak, T. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology, 2011, 77(4), 341-348.
54. Alexandrov, A.V.; Grotta, J.C. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology, 2002, 59(6), 862-867.
55. Saver, J.L. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke, 2007, 38(8), 2279-2283.
56. Khatri, P.; Wechsler, L.R.; Broderick, J.P. Intracranial hemorrhage associated with revascularization therapies. Stroke, 2007, 38(2), 431-440.
57. Park, J.H.; Ko, Y.; Kim, W.J.; Jang, M.S.; Yang, M.H.; Han, M.K.; Oh, C.W.; Park, S.H.; Lee, J.; Bae, H.J.; Gorelick, P.B. Is asymptomatic hemorrhagic transformation really innocuous? Neurology, 2012, 78(6), 421-426.
58. Dzialowski, I.; Pexman, J.H.; Barber, P.A.; Demchuk, A.M.; Buchan, A.M.; Hill, M.D. Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian alteplase for stroke effectiveness study registry. Stroke, 2007, 38(1), 75-79.
59. Kent, D.M.; Hinchey, J.; Price, L.L.; Levine, S.R.; Selker, H.P. In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous? Stroke, 2004, 35(5), 1141-1146.
60. Saqqur, M.; Tsivgoulis, G.; Molina, C.A.; Demchuk, A.M.; Siddiqui, M.; Alvarez-Sabin, J.; Uchino, K.; Calleja, S.; Alexandrov, A.V. Symptomatic intracerebral hemorrhage and recanalization after IV rt-PA: a multicenter study. Neurology, 2008, 71(17), 1304-1312.
61. Ahmed, N.; Davalos, A.; Eriksson, N.; Ford, G.A.; Glahn, J.; Hennerici, M.; Mikulik, R.; Kaste, M.; Lees, K.R.; Lindsberg, P.J.; Toni, D. Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register(SITS-ISTR). Arch. Neurol., 2010, 67(9), 1123-1130.
62. Lansberg, M.G.; Thijs, V.N.; Bammer, R.; Kemp, S.; Wijman, C.A.; Marks, M.P.; Albers, G.W. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke, 2007, 38(8), 2275-2278.
63. Kakuda, W.; Abo, M. [Intravenous administration of a tissue plasminogen activator beyond 3 hours of the onset of acute ischemic stroke-MRI-based decision making]. Brain Nerve, 2008, 60(10), 1173-1180.
64. Butcher, K.; Christensen, S.; Parsons, M.; De Silva, D.A.; Ebinger, M.; Levi, C.; Jeerakathil, T.; Campbell, B.C.; Barber, P.A.; Bladin, C.; Fink, J.; Tress, B.; Donnan, G.A.; Davis, S.M. Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation. Stroke, 2010, 41(1), 72-77.
65. Cucchiara, B.; Kasner, S.E.; Tanne, D.; Levine, S.R.; Demchuk, A.; Messe, S.R.; Sansing, L.; Lees, K.R.; Lyden, P. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment(SAINT) I and SAINT II Trials. Stroke, 2009, 40(9), 3067-3072.
66. Tanne, D.; Kasner, S.E.; Demchuk, A.M.; Koren-Morag, N.; Hanson, S.; Grond, M.; Levine, S.R. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation, 2002, 105(14), 1679-1685.
67. Mazya, M.; Egido, J.A.; Ford, G.A.; Lees, K.R.; Mikulik, R.; Toni, D.; Wahlgren, N.; Ahmed, N. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke(SITS) symptomatic intracerebral hemorrhage risk score. Stroke, 2012, 43(6), 1524-1531.
68. Lyden, P.D.; Zivin, J.A. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc. Brain Metab. Rev., 1993, 5(1), 1-16.
69. Lee, S.R.; Guo, S.Z.; Scannevin, R.H.; Magliaro, B.C.; Rhodes, K.J.; Wang, X.; Lo, E.H. Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators. Neurosci. Lett., 2007, 417(1), 1-5.
70. Sumii, T.; Lo, E.H. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke, 2002, 33(3), 831-836.
71. Aoki, T.; Sumii, T.; Mori, T.; Wang, X.; Lo, E.H. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke, 2002, 33(11), 2711-2717.
72. Barr, T.L.; Latour, L.L.; Lee, K.Y.; Schaewe, T.J.; Luby, M.; Chang, G.S.; El-Zammar, Z.; Alam, S.; Hallenbeck, J.M.; Kidwell, C.S.; Warach, S. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke, 2010, 41(3), e123-e128.
73. Bauer, A.T.; Burgers, H.F.; Rabie, T.; Marti, H.H. Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. J. Cereb. Blood Flow Metab., 2010, 30(4), 837-848.
74. Jin, R.; Yang, G.; Li, G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol. Dis., 2010, 38(3), 376-385.
75. Lapchak, P.A.; Chapman, D.F.; Zivin, J.A. Metalloproteinase inhibition reduces thrombolytic(tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke, 2000, 31(12), 3034-3040.
76. Yepes, M.; Sandkvist, M.; Moore, E.G.; Bugge, T.H.; Strickland, D.K.; Lawrence, D.A. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J. Clin. Invest., 2003, 112(10), 1533-1540.
77. Polavarapu, R.; Gongora, M.C.; Yi, H.; Ranganthan, S.; Lawrence, D.A.; Strickland, D.; Yepes, M. Tissue-type plasminogen activatormediated shedding of astrocytic low-density lipoprotein receptorrelated protein increases the permeability of the neurovascular unit. Blood, 2007, 109(8), 3270-3278.
78. Wang, X.; Lee, S.R.; Arai, K.; Tsuji, K.; Rebeck, G.W.; Lo, E.H. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat. Med., 2003, 9(10), 1313-1317.
79. Su, E.J.; Fredriksson, L.; Geyer, M.; Folestad, E.; Cale, J.; Andrae, J.; Gao, Y.; Pietras, K.; Mann, K.; Yepes, M.; Strickland, D.K.; Betsholtz, C.; Eriksson, U.; Lawrence, D.A. Activation of PDGFCC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat. Med., 2008, 14(7), 731-737.
80. Yao, Y.; Tsirka, S.E. Truncation of monocyte chemoattractant protein 1 by plasmin promotes blood-brain barrier disruption. J. Cell Sci., 2011, 124(Pt 9), 1486-1495.
81. del Zoppo, G.J.; Higashida, R.T.; Furlan, A.J.; Pessin, M.S.; Rowley, H.A.; Gent, M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke, 1998, 29(1), 4-11.
82. Lou, M.; Safdar, A.; Mehdiratta, M.; Kumar, S.; Schlaug, G.; Caplan, L.; Searls, D.; Selim, M. The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology, 2008, 71(18), 1417-1423.
83. Saposnik, G.; Fang, J.; Kapral, M.K.; Tu, J.V.; Mamdani, M.; Austin, P.; Johnston, S.C. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke. Stroke, 2012, 43(5), 1315-1322.
84. Strbian, D.; Engelter, S.; Michel, P.; Meretoja, A.; Sekoranja, L.; Ahlhelm, F.J.; Mustanoja, S.; Kuzmanovic, I.; Sairanen, T.; Forss, N.; Cordier, M.; Lyrer, P.; Kaste, M.; Tatlisumak, T. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann. Neurol., 2012, 71(5), 634-641.
85. Miller, D.J.; Simpson, J.R.; Silver, B. Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies. Neurohospitalist, 2011, 1(3), 138-147.
86. Heuschmann, P.U.; Berger, K.; Misselwitz, B.; Hermanek, P.; Leffmann, C.; Adelmann, M.; Buecker-Nott, H.J.; Rother, J.; Neundoerfer, B.; Kolominsky-Rabas, P.L. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke, 2003, 34(5), 1106-1113.
87. Aleu, A.; Mellado, P.; Lichy, C.; Kohrmann, M.; Schellinger, P.D. Hemorrhagic complications after off-label thrombolysis for ischemic stroke. Stroke, 2007, 38(2), 417-422.
88. Dhand, A.; Nakagawa, K.; Nagpal, S.; Gelfand, J.M.; Kim, A.S.; Smith, W.S.; Tihan, T. Cardiac rupture after intravenous t-PA administration in acute ischemic stroke. Neurocrit. Care 2010, 13(2), 261-262.
89. Kasner, S.E.; Villar-Cordova, C.E.; Tong, D.; Grotta, J.C. Hemopericardium and cardiac tamponade after thrombolysis for acute ischemic stroke. Neurology, 1998, 50(6), 1857-1859.
90. De Keyser, J.; Gdovinova, Z.; Uyttenboogaart, M.; Vroomen, P.C.; Luijckx, G.J. Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations. Stroke, 2007, 38(9), 2612-2618.
91. Kremen, S.A.; Wu, M.N.; Ovbiagele, B. Hemopericardium following intravenous thrombolysis for acute ischemic stroke. Cerebrovasc. Dis., 2005, 20(6), 478-479.
92. Broderick, J.; Connolly, S.; Feldmann, E.; Hanley, D.; Kase, C.; Krieger, D.; Mayberg, M.; Morgenstern, L.; Ogilvy, C.S.; Vespa, P.; Zuccarello, M. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke, 2007, 38(6), 2001-2023.
93. Morgenstern, L.B.; Hemphill, J.C. 3rd; Anderson, C.; Becker, K.; Broderick, J.P.; Connolly, E.S., Jr.; Greenberg, S.M.; Huang, J.N.; MacDonald, R.L.; Messe, S.R.; Mitchell, P.H.; Selim, M.; Tamargo, R.J. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2010, 41(9), 2108-2129.
94. Feigen, L.P.; Nicholson, N.S.; King, L.W.; Campion, J.G.; Tjoeng, F.S.; Panzer-Knodle, S.G. SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activatorinduced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis. J. Pharmacol. Exp. Ther., 1993, 267(3), 1191-1197.
95. Hong, T.T.; Driscoll, E.M.; White, A.J.; Sherigill, A.; Giboulot, T.A.; Lucchesi, B.R. Glycoprotein IIb/IIIa receptor antagonist(2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride(CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator. J. Pharmacol. Exp. Ther., 2003, 306(2), 616-623.
96. Hong, T.T.; Huang, J.; Lucchesi, B.R. Effect of thrombolysis on myocardial injury: recombinant tissue plasminogen activator vs alfimeprase. Am. J. Physiol. Heart Circ. Physiol., 2006, 290(3), H959-H967.
97. Rebello, S.S.; Huang, J.; Saito, K.; Saucedo, J.F.; Bates, E.R.; Lucchesi, B.R. Effect of time of 7E3 administration on rt-PAinduced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion. Eur. J. Pharmacol., 1999, 374(3), 399-410.
98. Haelewyn, B.; Risso, J.J.; Abraini, J.H. Human recombinant tissueplasminogen activator(alteplase): why not use the 'human' dose for stroke studies in rats? J. Cereb. Blood Flow Metab., 2010, 30(5), 900-903.
99. Killer, M.; Ladurner, G.; Kunz, A.B.; Kraus, J. Current endovascular treatment of acute stroke and future aspects. Drug Discov. Today, 2010, 15(15-16), 640-647.
100. Caplan, L.R. Worsening in ischemic stroke patients: is it time for a new strategy? Stroke, 2002, 33(6), 1443-1445.
101. Grotta, J.C.; Welch, K.M.; Fagan, S.C.; Lu, M.; Frankel, M.R.; Brott, T.; Levine, S.R.; Lyden, P.D. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke, 2001, 32(3), 661-668.
102. Alexandrov, A.V.; Demchuk, A.M.; Felberg, R.A.; Christou, I.; Barber, P.A.; Burgin, W.S.; Malkoff, M.; Wojner, A.W.; Grotta, J.C. High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-MHz transcranial doppler monitoring. Stroke, 2000, 31(3), 610-614.
103. Alexandrov, A.V.; Molina, C.A.; Grotta, J.C.; Garami, Z.; Ford, S.R.; Alvarez-Sabin, J.; Montaner, J.; Saqqur, M.; Demchuk, A.M.; Moye, L.A.; Hill, M.D.; Wojner, A.W. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N. Engl. J. Med., 2004, 351(21), 2170-2178.
104. Rubiera, M.; Alvarez-Sabin, J.; Ribo, M.; Montaner, J.; Santamarina, E.; Arenillas, J.F.; Huertas, R.; Delgado, P.; Purroy, F.; Molina, C.A. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke, 2005, 36(7), 1452-1456.
105. Heo, J.H.; Lee, K.Y.; Kim, S.H.; Kim, D.I. Immediate reocclusion following a successful thrombolysis in acute stroke: a pilot study. Neurology, 2003, 60(10), 1684-1687.
106. Lee, M.; Hong, K.S.; Saver, J.L. Efficacy of intra-arterial fibrinolysis for acute ischemic stroke: meta-analysis of randomized controlled trials. Stroke, 2010, 41(5), 932-937.
107. Grunwald, I.Q.; Wakhloo, A.K.; Walter, S.; Molyneux, A.J.; Byrne, J.V.; Nagel, S.; Kuhn, A.L.; Papadakis, M.; Fassbender, K.; Balami, J.S.; Roffi, M.; Sievert, H.; Buchan, A. Endovascular stroke treatment today. AJNR Am. J. Neuroradiol., 2011, 32(2), 238-243.
108. Abou-Chebl, A.; Bajzer, C.T.; Krieger, D.W.; Furlan, A.J.; Yadav, J.S. Multimodal therapy for the treatment of severe ischemic stroke combining GPIIb/IIIa antagonists and angioplasty after failure of thrombolysis. Stroke, 2005, 36(10), 2286-2288.
109. Bunc, M.; Kocijancic, I.J.; Pregelj, R.; Dolenc, V.V. Multimodal therapy for the treatment of severe ischemic stroke combining endovascular embolectomy and stenting of long intracranial artery occlusion. Case Report Med., 2010, 2010, 138023.
110. Jiang, Q.; Zhang, R.L.; Zhang, Z.G.; Ewing, J.R.; Jiang, P.; Divine, G.W.; Knight, R.A.; Chopp, M. Magnetic resonance imaging indexes of therapeutic efficacy of recombinant tissue plasminogen activator treatment of rat at 1 and 4 hours after embolic stroke. J. Cereb. Blood Flow Metab., 2000, 20(1), 21-27.
111. Gomez-Beldarrain, M.; Telleria, M.; Garcia-Monco, J.C. Peripheral arterial embolism during thrombolysis for stroke. Neurology, 2006, 67(6), 1096-1097.
112. Meissner, W.; Lempert, T.; Saeuberlich-Knigge, S.; Bocksch, W.; Pape, U.F. Fatal embolic myocardial infarction after systemic thrombolysis for stroke. Cerebrovasc. Dis., 2006, 22(2-3), 213-214.
113. Yasaka, M.; Yamaguchi, T.; Yonehara, T.; Moriyasu, H. Recurrent embolization during intravenous administration of tissue plasminogen activator in acute cardioembolic stroke. A case report. Angiology, 1994, 45(6), 481-484.
114. Hill, M.D.; Barber, P.A.; Takahashi, J.; Demchuk, A.M.; Feasby, T.E.; Buchan, A.M. Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke. CMAJ 2000, 162(9), 1281-1284.
115. Hill, M.D.; Lye, T.; Moss, H.; Barber, P.A.; Demchuk, A.M.; Newcommon, N.J.; Green, T.L.; Kenney, C.; Cole-Haskayne, A.; Buchan, A.M. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology, 2003, 60(9), 1525-1527.
116. Rudolf, J.; Grond, M.; Schmulling, S.; Neveling, M.; Heiss, W. Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase. Neurology, 2000, 55(4), 599-600.
117. Adams, H.P. Jr.; del Zoppo, G.; Alberts, M.J.; Bhatt, D.L.; Brass, L.; Furlan, A.; Grubb, R.L.; Higashida, R.T.; Jauch, E.C.; Kidwell, C.; Lyden, P.D.; Morgenstern, L.B.; Qureshi, A.I.; Rosenwasser, R.H.; Scott, P.A.; Wijdicks, E.F. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke, 2007, 38(5), 1655-1711.
118. Chodirker, W.B. Reactions to alteplase in patients with acute thrombotic stroke. CMAJ, 2000, 163(4), 387-389.
119. Wallon, D.; Girardie, P.; Bombois, S.; Lucas, C. Angioneurotic orolingual oedema following thrombolysis in acute ischaemic stroke. BMJ Case Rep., 2010, 2010.
120. Engelter, S.T.; Fluri, F.; Buitrago-Tellez, C.; Marsch, S.; Steck, A.J.; Ruegg, S.; Lyrer, P.A. Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke. J. Neurol., 2005, 252(10), 1167-1170.
121. Tan, C.H.; Tang, S.C.; Lin, R.J.; Jeng, J.S. Neurological picture. Orolingual angio-oedema after alteplase therapy in a stroke patient concurrently using angiotensin II receptor blocker. J. Neurol. Neurosurg. Psychiatry, 2010, 81(10), 1079.
122. Molinaro, G.; Gervais, N.; Adam, A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach. Stroke, 2002, 33(6), 1712-1716.
123. Aronowski, J.; Strong, R.; Grotta, J.C. Reperfusion injury: demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. J. Cereb. Blood Flow Metab., 1997, 17(10), 1048-1056.
124. Heo, J.H.; Han, S.W.; Lee, S.K. Free radicals as triggers of brain edema formation after stroke. Free Radic. Biol. Med., 2005, 39(1), 51-70.
125. Awasthi, D.; Church, D.F.; Torbati, D.; Carey, M.E.; Pryor, W.A. Oxidative stress following traumatic brain injury in rats. Surg. Neurol., 1997, 47(6), 575-581; discussion 581-582.
126. Tomimoto, H.; Shibata, M.; Ihara, M.; Akiguchi, I.; Ohtani, R.; Budka, H. A comparative study on the expression of cyclooxygenase and 5-lipoxygenase during cerebral ischemia in humans. Acta Neuropathol., 2002, 104(6), 601-607.
127. Ueno, M.; Tomimoto, H.; Akiguchi, I.; Wakita, H.; Sakamoto, H. Blood-brain barrier disruption in white matter lesions in a rat model of chronic cerebral hypoperfusion. J. Cereb. Blood Flow Metab., 2002, 22(1), 97-104.
128. Attwell, D.; Buchan, A.M.; Charpak, S.; Lauritzen, M.; Macvicar, B.A.; Newman, E.A. Glial and neuronal control of brain blood flow. Nature, 2010, 468(7321), 232-243.
129. HSTR, The Helsinki Stroke Thrombolysis Registry Group. Cerebral edema in acute ischemic stroke patients treated with intravenous thrombolysis. Int. J. Stroke, 2012, [Epub ahead of print].
130. Chen, R.L.; Balami, J.S.; Esiri, M.M.; Chen, L.K.; Buchan, A.M. Ischemic stroke in the elderly: an overview of evidence. Nat. Rev. Neurol., 2010, 6(5), 256-265.
131. Hacke, W.; Schwab, S.; Horn, M.; Spranger, M.; De Georgia, M.; von Kummer, R. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch. Neurol., 1996, 53(4), 309-315.
132. Huttner, H.B.; Schwab, S. Malignant middle cerebral artery infarction: clinical characteristics, treatment strategies, and future perspectives. Lancet Neurol., 2009, 8(10), 949-958.
133. Jaramillo, A.; Gongora-Rivera, F.; Labreuche, J.; Hauw, J.J.; Amarenco, P. Predictors for malignant middle cerebral artery infarctions: a postmortem analysis. Neurology, 2006, 66(6), 815-820.
134. ESO, The European Stroke Organisation(ESO) Executive Committee and the ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc. Dis., 2008, 25(5), 457-507.
135. Sutherland, B.A.; Papadakis, M.; Chen, R.L.; Buchan, A.M. Cerebral blood flow alteration in neuroprotection following cerebral ischaemia. J. Physiol., 2011, 589(Pt 17), 4105-4114.
136. Hauck, E.F.; Apostel, S.; Hoffmann, J.F.; Heimann, A.; Kempski, O. Capillary flow and diameter changes during reperfusion after global cerebral ischemia studied by intravital video microscopy. J. Cereb. Blood Flow Metab., 2004, 24(4), 383-391.
137. Leffler, C.W.; Busija, D.W.; Mirro, R.; Armstead, W.M.; Beasley, D.G. Effects of ischemia on brain blood flow and oxygen consumption of newborn pigs. Am. J. Physiol., 1989, 257(6 Pt 2), H1917-H1926.
138. Yemisci, M.; Gursoy-Ozdemir, Y.; Vural, A.; Can, A.; Topalkara, K.; Dalkara, T. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat. Med., 2009, 15(9), 1031-1037.
139. Kilic, E.; Bahr, M.; Hermann, D.M. Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations. Stroke, 2001, 32(11), 2641-2647.
140. Cipolla, M.J.; Lessov, N.; Clark, W.M.; Haley, E.C. Jr. Postischemic attenuation of cerebral artery reactivity is increased in the presence of tissue plasminogen activator. Stroke, 2000, 31(4), 940-945.
141. Nassar, T.; Akkawi, S.; Shina, A.; Haj-Yehia, A.; Bdeir, K.; Tarshis, M.; Heyman, S.N.; Higazi, A.A. In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood, 2004, 103(3), 897-902.
142. Kilic, E.; Kilic, U.; Matter, C.M.; Luscher, T.F.; Bassetti, C.L.; Hermann, D.M. Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase. Stroke, 2005, 36(2), 332-336.
143. Wang, Y.F.; Tsirka, S.E.; Strickland, S.; Stieg, P.E.; Soriano, S.G.; Lipton, S.A. Tissue plasminogen activator(tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med., 1998, 4(2), 228-231.
144. Harston, G.W.; Sutherland, B.A.; Kennedy, J.; Buchan, A.M. The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity. J. Cereb. Blood Flow Metab., 2010, 30(11), 1804-1816.
145. Benchenane, K.; Berezowski, V.; Ali, C.; Fernandez-Monreal, M.; Lopez-Atalaya, J.P.; Brillault, J.; Chuquet, J.; Nouvelot, A.; MacKenzie, E.T.; Bu, G.; Cecchelli, R.; Touzani, O.; Vivien, D. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related proteinmediated transcytosis. Circulation, 2005, 111(17), 2241-2249.
146. Harada, T.; Kano, T.; Katayama, Y.; Matsuzaki, T.; Tejima, E.; Koshinaga, M. Tissue plasminogen activator extravasated through the cerebral vessels: evaluation using a rat thromboembolic stroke model. Thromb. Haemost., 2005, 94(4), 791-796.
147. Goto, H.; Fujisawa, H.; Oka, F.; Nomura, S.; Kajiwara, K.; Kato, S.; Fujii, M.; Maekawa, T.; Suzuki, M. Neurotoxic effects of exogenous recombinant tissue-type plasminogen activator on the normal rat brain. J. Neurotrauma, 2007, 24(4), 745-752.
148. Kaur, J.; Zhao, Z.; Klein, G.M.; Lo, E.H.; Buchan, A.M. The neurotoxicity of tissue plasminogen activator? J. Cereb. Blood Flow Metab., 2004, 24(9), 945-963.
149. Nicole, O.; Docagne, F.; Ali, C.; Margaill, I.; Carmeliet, P.; MacKenzie, E.T.; Vivien, D.; Buisson, A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptormediated signaling. Nat. Med., 2001, 7(1), 59-64.
150. Park, L.; Gallo, E.F.; Anrather, J.; Wang, G.; Norris, E.H.; Paul, J.; Strickland, S.; Iadecola, C. Key role of tissue plasminogen activator in neurovascular coupling. Proc. Natl. Acad. Sci. USA, 2008, 105(3), 1073-1078.
151. Martin, A.M.; Kuhlmann, C.; Trossbach, S.; Jaeger, S.; Waldron, E.; Roebroek, A.; Luhmann, H.J.; Laatsch, A.; Weggen, S.; Lessmann, V.; Pietrzik, C.U. The functional role of the second NPXY motif of the LRP1 beta-chain in tissue-type plasminogen activator-mediated activation of N-methyl-D-aspartate receptors. J. Biol. Chem., 2008, 283(18), 12004-12013.
152. Zhang, C.; An, J.; Strickland, D.K.; Yepes, M. The low-density lipoprotein receptor-related protein 1 mediates tissue-type plasminogen activator-induced microglial activation in the ischemic brain. Am. J. Pathol., 2009, 174(2), 586-594.
153. Kilic, E.; Kilic, U.; Bahr, M.; Hermann, D.M. Tissue plasminogen activator-induced ischemic injury is reversed by NMDA antagonist MK-801 in vivo. Neurodegener. Dis., 2005, 2(2), 49-55.
154. Rogove, A.D.; Siao, C.; Keyt, B.; Strickland, S.; Tsirka, S.E. Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system. J. Cell Sci., 1999, 112(Pt 22), 4007-4016.
155. Casse, F.; Bardou, I.; Danglot, L.; Briens, A.; Montagne, A.; Parcq, J.; Alahari, A.; Galli, T.; Vivien, D.; Docagne, F. Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals. J. Neurosci., 2012, 32(15), 5186-5199.
156. Correa, F.; Gauberti, M.; Parcq, J.; Macrez, R.; Hommet, Y.; Obiang, P.; Hernangomez, M.; Montagne, A.; Liot, G.; Guaza, C.; Maubert, E.; Ali, C.; Vivien, D.; Docagne, F. Tissue plasminogen activator prevents white matter damage following stroke. J. Exp. Med., 2011, 208(6), 1229-1242.
157. Kim, Y.H.; Park, J.H.; Hong, S.H.; Koh, J.Y. Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator. Science, 1999, 284(5414), 647-650.
158. Haile, W.B.; Wu, J.; Echeverry, R.; Wu, F.; An, J.; Yepes, M. Tissue-type plasminogen activator has a neuroprotective effect in the ischemic brain mediated by neuronal TNF-alpha. J. Cereb. Blood Flow Metab., 2012, 32(1), 57-69.
159. Liot, G.; Roussel, B.D.; Lebeurrier, N.; Benchenane, K.; Lopez-Atalaya, J.P.; Vivien, D.; Ali, C. Tissue-type plasminogen activator rescues neurones from serum deprivation-induced apoptosis through a mechanism independent of its proteolytic activity. J. Neurochem., 2006, 98(5), 1458-1464.
160. Yi, J.S.; Kim, Y.H.; Koh, J.Y. Infarct reduction in rats following intraventricular administration of either tissue plasminogen activator(tPA) or its non-protease mutant S478A-tPA. Exp. Neurol., 2004, 189(2), 354-360.
161. Macrez, R.; Obiang, P.; Gauberti, M.; Roussel, B.; Baron, A.; Parcq, J.; Casse, F.; Hommet, Y.; Orset, C.; Agin, V.; Bezin, L.; Berrocoso, T.G.; Petersen, K.U.; Montaner, J.; Maubert, E.; Vivien, D.; Ali, C. Antibodies preventing the interaction of tissue-type plasminogen activator with N-methyl-D-aspartate receptors reduce stroke damages and extend the therapeutic window of thrombolysis. Stroke, 2011, 42(8), 2315-2322.
162. Lopez-Atalaya, J.P.; Roussel, B.D.; Ali, C.; Maubert, E.; Petersen, K.U.; Berezowski, V.; Cecchelli, R.; Orset, C.; Vivien, D. Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects. Stroke, 2007, 38(3), 1036-1043.
163. Medcalf, R.L. Desmoteplase: discovery, insights and opportunities for ischaemic stroke. Br. J. Pharmacol., 2012, 165(1), 75-89.
164. Kidwell, C.S.; Latour, L.; Saver, J.L.; Alger, J.R.; Starkman, S.; Duckwiler, G.; Jahan, R.; Vinuela, F.; Kang, D.W.; Warach, S. Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc. Dis., 2008, 25(4), 338-343.
165. Warach, S.; Latour, L.L. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke, 2004, 35(11 Suppl 1), 2659-2661.
166. Rodriguez-Gonzalez, R.; Millan, M.; Sobrino, T.; Miranda, E.; Brea, D.; de la Ossa, N.P.; Blanco, M.; Perez, J.; Dorado, L.; Castellanos, M.; Lomas, D.A.; Moro, M.A.; Davalos, A.; Castillo, J. The natural tissue plasminogen activator inhibitor neuroserpin and acute ischaemic stroke outcome. Thromb. Haemost., 2011, 105(3), 421-429.
167. Rodriguez-Gonzalez, R.; Sobrino, T.; Rodriguez-Yanez, M.; Millan, M.; Brea, D.; Miranda, E.; Moldes, O.; Perez, J.; Lomas, D.A.; Leira, R.; Davalos, A.; Castillo, J. Association between neuroserpin and molecular markers of brain damage in patients with acute ischemic stroke. J. Transl. Med., 2011, 9, 58.
168. Qian, Z.; Gilbert, M.E.; Colicos, M.A.; Kandel, E.R.; Kuhl, D. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature, 1993, 361(6411), 453-457.
169. Tsirka, S.E.; Gualandris, A.; Amaral, D.G.; Strickland, S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature, 1995, 377(6547), 340-344.
170. Yepes, M.; Sandkvist, M.; Coleman, T.A.; Moore, E.; Wu, J.Y.; Mitola, D.; Bugge, T.H.; Lawrence, D.A. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J. Clin. Invest., 2002, 109(12), 1571-1578.
171. Bladin, C.F.; Alexandrov, A.V.; Bellavance, A.; Bornstein, N.; Chambers, B.; Cote, R.; Lebrun, L.; Pirisi, A.; Norris, J.W. Seizures after stroke: a prospective multicenter study. Arch. Neurol., 2000, 57(11), 1617-1622.
172. Lamy, C.; Domigo, V.; Semah, F.; Arquizan, C.; Trystram, D.; Coste, J.; Mas, J.L. Early and late seizures after cryptogenic ischemic stroke in young adults. Neurology, 2003, 60(3), 400-404.
173. Ryvlin, P.; Montavont, A.; Nighoghossian, N. Optimizing therapy of seizures in stroke patients. Neurology, 2006, 67(12 Suppl 4), S3-S9.
174. Hafeez, F.; Razzaq, M.A.; Levine, R.L.; Ramirez, M.A. Reperfusion seizures: a manifestation of cerebral reperfusion injury after administration of recombinant tissue plasminogen activator for acute ischemic stroke. J. Stroke Cerebrovasc. Dis., 2007, 16(6), 273-277.
175. Rodan, L.H.; Aviv, R.I.; Sahlas, D.J.; Murray, B.J.; Gladstone, J.P.; Gladstone, D.J. Seizures during stroke thrombolysis heralding dramatic neurologic recovery. Neurology, 2006, 67(11), 2048-2049.
176. Alvarez, V.; Rossetti, A. O.; Papavasileiou, V.; Michel, P., Acute seizures in acute ischemic stroke: does thrombolysis have a role to play? J Neurol 2013, 260(1), 55-61.
177. De Reuck, J.; Van Maele, G. Acute ischemic stroke treatment and the occurrence of seizures. Clin. Neurol. Neurosurg., 2010, 112(4), 328-331.
178. Pawlak, R.; Melchor, J.P.; Matys, T.; Skrzypiec, A.E.; Strickland, S. Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc. Natl. Acad. Sci. USA, 2005, 102(2), 443-448.
179. Pawlak, R.; Strickland, S. Tissue plasminogen activator and seizures: a clot-buster's secret life. J. Clin. Invest., 2002, 109(12), 1529-1531.